Because the activation or modulation of apoptosis-related proteins, such as p53, p21, Bcl-2, Bax and caspases, constitutes one of the strategies for radiotherapy-induced cancer elimination, therapeutic reagents that enhance the effects of radiotherapy should also target the apoptosis machinery in cells [41,42,43]. Here, BCL2 is linked to cancer.